decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2002 / B-02-016
Subscribe or sign in to view the full article.
Article Overview
This Medicare program memorandum explains a change request from CMS affecting DMERC processing for oral anti-cancer drug claims. It covers the addition of internal WW identifiers, references the related drug product and its NDC-based billing context, and includes effective, implementation, and retention dates. The article is relevant to Medicare DMEPOS billing staff, DMERC operations, and coding or reimbursement professionals who track CMS program memoranda and drug-related processing updates.
Why This Topic Matters
It helps readers understand a CMS processing update that affects how a specific oral anti-cancer drug source is recognized in internal systems and how the change is timed for implementation. This is useful for Medicare billing, claims processing, and compliance teams monitoring program instructions.
What You Will Learn
- What CMS announced in this program memorandum
- How the change relates to oral anti-cancer drug processing
- Which internal identifiers were added for DMERC system use
- What dates govern the memorandum’s coverage and implementation
- Which Medicare operational categories are referenced in the memo
Who Should Read This
- Medicare billing staff
- DMEPOS suppliers
- DMERC claims processors
- Medical coding professionals
- Revenue cycle and compliance teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com